Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8452W HIGH $71.50
Volume
40.81 K
Value Traded
319.73 K
Short % Float
1.26%
-14.7%Week
-29.36%1 Month
-54.04%3 Month
-43.54%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.83 M
EPS (TTM)
-10.51
P/E Ratio
-
Ent. Value
-196.06 K
Total Shares
1.63 M
Float Shares
1.14 M
Insiders
30.04%
Institutions
2.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ERNA Catalyst Timeline
Dated clinical, regulatory and corporate events for Ernexa Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ernexa Therapeutics Inc.
136Total events
17Upcoming
14Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCERNA-101Preclinical
ERNA-101 plus anti-PD-1 showed complete tumor clearance and 100% survival in ovarian cancer model
ovarian cancersource ↗
▼Pipeline PrioritizationERNA-201DiscontinuedCorporate
Ernexa pauses additional preclinical development expenditures on ERNA-201 to focus on ERNA-101
▲Preclinical PoCERNA-101Preclinical
ERNA-101 repeat-dose GLP toxicology showed no related adverse findings at any dose level
ovarian cancersource ↗
▲IND Enabling CompleteERNA-101Preclinical
Core IND-enabling safety studies complete
platinum-resistant ovarian cancersource ↗
●R&D DayPresentation
Ernexa CEO to present at H.C. Wainwright 28th Annual Global Investment Conference
▲Preclinical PoCERNA-201DiscontinuedPreclinical
ERNA-201 demonstrates disease-modifying activity in CIA model
rheumatoid arthritis and inflammatory joint diseasesource ↗
▲Platform ValidationPreclinical
ERNA-201 results validate synthetic iMSC platform beyond oncology
▼Program DiscontinuationERNA-201DiscontinuedCorporate
Ernexa pauses additional preclinical development expenditures on ERNA-201
rheumatoid arthritis and inflammatory joint diseasesource ↗
●Pipeline PrioritizationCorporate
Ernexa sharpens oncology strategy, prioritizes ERNA-101
oncologysource ↗
▲Preclinical PoCERNA-101Preclinical
ERNA-101 50-day GLP toxicology study showed no related adverse findings
ovarian cancersource ↗
▲IND Enabling CompleteERNA-101Preclinical
Core IND-enabling safety studies for ERNA-101 completed
platinum-resistant ovarian cancersource ↗
▲Preclinical PoCERNA-101Preclinical
Independent CRO reproduces ERNA-101 + anti-PD-1 complete tumor clearance and durable survival in larger preclinical study
ovarian cancersource ↗
◆Manufacturing MilestoneERNA-101CMC / Inspection
Release of first GMP clinical product batch expected in Q3 2026
◆IND Enabling CompleteERNA-101Preclinical
Completion of required IND-enabling studies expected in Q3 2026
●Pre IND MeetingERNA-101FDA Meeting
FDA Pre-IND meeting for ERNA-101 completed
advanced cancersource ↗
●Manufacturing MilestoneERNA-101CMC / Inspection
Initiation of technology transfer activities to support future manufacturing scalability
●IND Enabling CompleteERNA-101Preclinical
Advancement of IND-enabling studies and regulatory documentation
▲Manufacturing MilestoneERNA-101CMC / Inspection
Process development for ERNA-101 manufacturing successfully completed
advanced cancer and autoimmune diseasesource ↗
▲Preclinical PoCERNA-101Preclinical
Preclinical data demonstrating complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade
ovarian cancersource ↗
▲Preclinical PoCERNA-101Preclinical
Preclinical ovarian cancer data for ERNA-101 demonstrated complete tumor elimination and 100% survival in models when combined with PD-1 blockade
ovarian cancersource ↗
▲Preclinical PoCERNA-101Preclinical
ERNA-101 in combination with PD-1 blockade achieves 100% survival and complete tumor clearance in syngeneic ovarian cancer models
ovarian cancersource ↗
●Manufacturing MilestoneERNA-101CMC / Inspection
Completion of ERNA-101 clinical manufacturing process development
platinum-resistant ovarian cancersource ↗
◆Oral PresentationPresentation
Ernexa Therapeutics to participate in Virtual Investor Closing Bell Series
▼Equity OfferingCorporate
Pricing of $10.5 million public offering of common stock and warrants
▲Pre IND MeetingERNA-101FDA Meeting
Successful Pre-IND meeting with FDA for ERNA-101
ovarian cancersource ↗
▲Other Regulator MilestoneEx-US Regulatory
Selected for JETRO Japan Entry Acceleration Program (JEAP)
▲Pre IND MeetingFDA Meeting
Successful Pre-IND meeting with FDA for ERNA-101 in ovarian cancer
ovarian cancersource ↗
▲Manufacturing MilestoneERNA-101CMC / Inspection
Tech transfer for clinical manufacturing of ERNA-101 underway
ovarian cancersource ↗
◆Trial InitiationERNA-101Trial
First clinical trial initiation expected in early 2026
ovarian cancersource ↗
◆Oral PresentationERNA-101Presentation
Oral presentation of preclinical data on ERNA-101 at ASH Annual Meeting
ovarian cancersource ↗
◆Oral PresentationERNA-101Presentation
Oral presentation at ASH 2025 on preclinical data for ERNA-101
ovarian cancersource ↗
▲Management ChangeCorporate
Appointment of Dr. Ira S. Winer to Scientific and Medical Advisory Board
◆Oral PresentationPresentation
Panel: Challenges of Navigating Development & How To Get To The Clinic at Cell 2025
▲Partnership / LicenseCorporate
Partnership agreement with Cellipont Bioservices for ERNA-101 clinical manufacturing
◆Oral PresentationPresentation
President & CEO Sanjeev Luther to participate in panel at 5th Annual iPSC Drug Development Summit
◆Oral PresentationERNA-101Presentation
Presented new data on ERNA-101 at AACR Special Conference in Cancer Research
ovarian cancersource ↗
◆Oral PresentationERNA-101Presentation
Oral presentation of preclinical data for ERNA-101 at AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research
high-grade serous ovarian cancersource ↗
◆Poster PresentationERNA-101Presentation
Poster presentation on ERNA-101 at AACR Special Conference
ovarian cancersource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
Past FDA Catalysts and PDUFA Decisions
How ERNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-13 | ERNA-101 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 94%
Micro Cap(rank 619 of 658)
Percentile Rank
Ernexa Therapeutics Inc. faces pipeline headwinds (21/100), with $240M risk-adjusted pipeline value, led by IRX-2 in Squamous Cell Carcinoma of the Oral Cavity (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IRX-2 Monoclonal antibodyCompletedNCT02609386 | Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | COMPLETED | 105 | Feb 28, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ERNA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ERNA-101 | cancer | 2026-09-30 | No ERNA-101-related adverse findings were observed at any dose level tested in a 50-day GLP toxicology study in tumor-bearing mice with an intact immune system.; No teratoma formation was observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase.; No significant ERNA-101 signal was detected in tumor-free animals or non-tumor tissues.Read More | Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cherington Charles10% Owner | Buy | 4,000,000 6,779,440 held | $0.50 | 02/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ERNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ERNA for Q2 2026. | ||||
ERNA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ERNA ranks across every disease it competes in
Competitive Position is a premium feature
See how ERNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialERNA News
-ERNA
Oct 1, 2026▼ -7.5%on this news
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Ernexa Therapeutics has appointed Dr. Robert J. Spiegel to its Board, enhancing its oncology focus as it advances ERNA-101 towards clinical trials. The drug has demonstrated complete tumor clearance and 100% survival in preclinical studies. Ernexa aims for an IND submission in Q4 2026 and a first-in-human study in Q1 2027, targeting difficult-to-treat solid tumors.
Read more →-ERNA
Sep 30, 2026Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Ernexa Therapeutics announced positive results from three IND-enabling safety studies of ERNA-101, its iMSC therapy for cancer. The studies showed no adverse findings in toxicology, no teratoma formation, and effective tumor-homing capabilities. These results support the safety and efficacy of ERNA-101 as the company prepares for an IND submission in Q4 2026.
Read more →-ERNA
Sep 29, 2026▼ -8.9%on this newsshared move
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Ernexa Therapeutics has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa. CEO Sanjeev Luther will present the company's focused oncology strategy, particularly highlighting ERNA-101 for platinum-resistant ovarian cancer. The presentation will showcase the promising preclinical data supporting ERNA-101's efficacy and the innovative synthetic iMSC platform. The company is on track for an IND submission in 2026.
Read more →-ERNA
Sep 17, 2026Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Ernexa Therapeutics has appointed Dr. Robert J. Spiegel to its Board of Directors, enhancing its leadership as it advances ERNA-101 towards clinical development. Dr. Spiegel's extensive experience in oncology and regulatory affairs is expected to provide valuable insights as the company focuses on addressing unmet needs in ovarian cancer treatment. The appointment comes at a critical time for Ernexa as it prepares for clinical evaluation of its lead cell therapy candidate.
Read more →-ERNA
Sep 15, 2026Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
Ernexa Therapeutics reported positive preclinical results for ERNA-201, demonstrating its potential in treating inflammatory diseases. The findings support the versatility of the company's synthetic iMSC platform. Ernexa is prioritizing resources on ERNA-101, which is set for a first-in-human study in platinum-resistant ovarian cancer. The company aims to broaden its oncology strategy while preserving ERNA-201 for future development.
Read more →-ERNA
Sep 14, 2026Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ernexa Therapeutics announced that its President and CEO, Sanjeev Luther, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The presentation will cover the company's oncology strategy and progress with its lead cell therapy candidate, ERNA-101. Ernexa is focused on developing innovative cell therapies for advanced cancers, particularly ovarian cancer.
Read more →-ERNA
Aug 27, 2026Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Ernexa Therapeutics participated in the Virtual Investor "Why Now" on-demand conference, where CEO Sanjeev Luther discussed the company's investment thesis. He emphasized the significance of transitioning to a clinical-stage company and highlighted the promising preclinical results of their lead candidate, ERNA-101, aimed at treating ovarian cancer. The company is preparing for an IND submission and its first Phase 1 clinical study.
Read more →-ERNA
Aug 10, 2026▲ +7.6%on this news
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Ernexa Therapeutics has appointed David Polinsky to its Board of Directors as the company approaches a pivotal stage in its development. With plans for an IND submission for ERNA-101 in Q3 2026 and a Phase 1 clinical study initiation in Q4 2026, the leadership team aims to strengthen its operational infrastructure. Polinsky's extensive experience in biotechnology and corporate governance is expected to guide Ernexa through its upcoming clinical milestones.
Read more →-ERNA
Jul 24, 2026Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
Ernexa Therapeutics' CEO Sanjeev Luther highlights the potential of ERNA-101 in transforming cancer treatment through combination therapies. The therapy aims to target immunologically 'cold' tumors, enhancing the effectiveness of existing immunotherapies. Encouraging preclinical results support its development, with plans for an IND submission in Q3 2026 and a Phase 1 study to follow.
Read more →-ERNA
Jul 15, 2026▲ +11.1%on this news
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Ernexa Therapeutics announced successful independent validation of its lead therapy, ERNA-101, demonstrating complete tumor clearance and long-term survival in a preclinical study. The combination of ERNA-101 with anti-PD-1 therapy showed significant results, with plans for an IND submission in Q3 2026 and a Phase 1 trial expected in Q4 2026. This study strengthens the foundation for ERNA-101's clinical development.
Read more →-ERNA
Jul 14, 2026▲ +9.4%on this news· ran to +21% by day 1shared move
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics is advancing its lead cell therapy candidate, ERNA-101, aimed at treating ovarian cancer. The company plans to submit an IND application in Q3 2026, with a first-in-human Phase 1 study expected to start in Q4 2026. CEO Sanjeev Luther highlighted the potential of ERNA-101 to convert immunologically 'cold' tumors into detectable targets for the immune system. Encouraging preclinical data supports the efficacy of ERNA-101 in tumor clearance and survival rates.
Read more →-ERNA
Jun 25, 2026▲ +17.5%on this news
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Ernexa Therapeutics has launched its CEO Corner platform to provide insights into the company's mission and scientific strategy. The inaugural video features CEO Sanjeev Luther discussing the company's commitment to developing innovative cell therapies for advanced cancer and autoimmune diseases. The platform aims to enhance communication with stakeholders and emphasize the importance of accessibility and affordability in treatment.
Read more →-ERNA
Jun 17, 2026Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics is advancing its lead oncology candidate, ERNA-101, with a planned IND submission in Q3 2026 and a first-in-human study expected in Q4 2026. The therapy aims to treat immunologically cold tumors, showing promising preclinical results. The company has completed key manufacturing and regulatory milestones, positioning itself for clinical-stage development.
Read more →-ERNA
Jun 9, 2026▼ -8%on this news
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Ernexa Therapeutics highlighted the unmet needs in ovarian cancer during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion focused on the limitations of current treatments and the potential of ERNA-101, which aims to activate immune responses in the tumor microenvironment. The engineered cell therapy may offer scalable solutions that improve accessibility for patients facing difficult-to-treat cancers.
Read more →-ERNA
May 27, 2026Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics has made significant strides in the development of its lead candidate, ERNA-101, by completing critical manufacturing milestones and transitioning to GMP manufacturing. The company is on track for an Investigational New Drug (IND) submission in Q3 2026, which will pave the way for its first-in-human clinical study. These advancements reflect Ernexa's commitment to addressing unmet medical needs in cancer and autoimmune diseases.
Read more →-ERNA
May 20, 2026Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, who discusses the challenges in treating ovarian cancer and the potential of ERNA-101. The segment highlights the limitations of current therapies and elevates Ernexa's innovative approach with preclinical data showing successful tumor eradication. Dr. Ratner emphasizes the advantages of the company's engineered allogeneic iMSC platform, which aims to enhance accessibility and efficiency in treatment. This development underscores Ernexa's commitment to addressing significant unmet needs in the cancer treatment landscape.
Read more →-ERNA
May 11, 2026Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Ernexa Therapeutics has released a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, discussing the challenges in ovarian cancer treatment and the potential of their lead candidate, ERNA-101. The segment emphasizes the need for more effective therapies and outlines how ERNA-101 could enhance patient outcomes. Additionally, the company will participate in a Virtual Investor Closing Bell event on May 13, 2026, to discuss preclinical data for ERNA-101.
Read more →-ERNA
May 6, 2026▲ +51.4%on this news· ran to +96% by day 1shared move
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Ernexa Therapeutics announced remarkable preclinical results for its lead cell therapy candidate, ERNA-101, which demonstrated complete tumor elimination and 100% long-term survival in ovarian cancer models. The therapy, in combination with PD-1 blockade, showed significant efficacy by converting the tumor microenvironment from immunosuppressive to immune-activated. With plans to advance ERNA-101 towards human trials, Ernexa aims to address the challenges posed by ovarian cancer treatments traditionally hindered by a non-responsive immune environment. The company intends to explore additional indications for ERNA-101 in other solid tumors as well.
Read more →-ERNA
Apr 30, 2026▼ -21.2%on this news
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Ernexa Therapeutics has announced a 1-for-25 reverse stock split effective May 4, 2026, to comply with Nasdaq's minimum bid price requirement. This move aims to enhance the company's financial standing and visibility among investors. The split will adjust the number of shares outstanding while maintaining the rights of existing shares. The company is focused on advancing its clinical programs and strengthening its market position.
Read more →-ERNA
Mar 31, 2026▲ +5.3%on this news
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Ernexa Therapeutics is advancing its lead product candidate, ERNA-101, toward first-in-human clinical trials anticipated to begin in Q4 2026. The company has demonstrated promising preclinical data showcasing its potential in treating platinum-resistant ovarian cancer. Key regulatory milestones, including an IND submission expected in Q3 2026, are set to support the company's transition from preclinical to clinical stages. Ernexa plans to leverage recent financing to fulfill critical upcoming milestones, positioning itself for significant value creation in the near term.
Read more →About Ernexa Therapeutics Inc.
Headquarters1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141
BIOPHARMAWATCH ELITE PLUS
Trade the next ERNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime